Skip to main content

Aurinia Pharmaceuticals Inc

For the period ended Dec 31, 2023. Filed Feb 15, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 15, 2024

AUPH$16.62+1.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 16. Form 10-K Summary

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AURINIA PHARMACEUTICALS INC.
February 14, 2024By:/s/ Peter Greenleaf
Peter Greenleaf
Chief Executive Officer
(Principal Executive Officer)

SIGNATURES AND POWER OF ATTORNEY

We, the undersigned directors and officers of Aurinia Pharmaceuticals Inc., hereby severally constitute and appoint Peter Greenleaf and Joseph Miller, and each of them singly, our true and lawful attorneys, with full power to them, and to each of them singly, to sign for us and in our names in the capacities indicated below, any and all amendments to this Annual Report on Form 10-K, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of us might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

NameTitleDate
/s/ Peter GreenleafPresident, Chief Executive Officer, DirectorFebruary 14, 2024
Peter Greenleaf(Principal Executive Officer)
/s/ Joseph MillerChief Financial OfficerFebruary 14, 2024
Joseph Miller(Principal Financial and Accounting Officer)
/s/ Brinda BalakrishnanDirectorFebruary 14, 2024
Brinda Balakrishnan, M.D., Ph.D.
/s/ Jeffrey A. BaileyDirectorFebruary 14, 2024
Jeffrey A. Bailey
/s/ Dr. Karen SmithDirectorFebruary 14, 2024
Dr. Karen Smith
/s/ Dr. Robert T. FosterDirectorFebruary 14, 2024
Dr. Robert T. Foster
/s/ David R.W. JayneDirectorFebruary 14, 2024
David R.W. Jayne, M.D., FRCP, FRCPE, FMedSci
/s/ Jill LeversageDirectorFebruary 14, 2024
Jill Leversage
/s/ R. Hector MacKay-DunnDirectorFebruary 14, 2024
R. Hector MacKay-Dunn, J.D., Q.C.
/s/ Daniel BillenChairmanFebruary 14, 2024
Daniel Billen, Ph.D.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.